Ampio Pharmaceuticals (AMPE) Competitors

Ampio Pharmaceuticals (NYSE:AMPE) and Avalo Therapeutics (NASDAQ:AVTX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, profitability, community ranking, dividends, valuation and analyst recommendations.

Which has more volatility & risk, AMPE or AVTX?

Ampio Pharmaceuticals has a beta of 1.76, meaning that its stock price is 76% more volatile than the S&P 500. Comparatively, Avalo Therapeutics has a beta of 1.21, meaning that its stock price is 21% more volatile than the S&P 500.

Do analysts rate AMPE or AVTX?

Avalo Therapeutics has a consensus price target of $10.00, indicating a potential upside of 7,042.86%. Given Avalo Therapeutics' higher possible upside, analysts clearly believe Avalo Therapeutics is more favorable than Ampio Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ampio Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A
Avalo Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Is AMPE or AVTX more profitable?

Ampio Pharmaceuticals has a net margin of 0.00% compared to Avalo Therapeutics' net margin of -146.01%. Avalo Therapeutics' return on equity of 0.00% beat Ampio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ampio Pharmaceuticals	N/A	-139.54%	-106.90%
Avalo Therapeutics	-146.01%	N/A	-75.99%

Does the media prefer AMPE or AVTX?

In the previous week, Ampio Pharmaceuticals and Ampio Pharmaceuticals both had 2 articles in the media. Ampio Pharmaceuticals' average media sentiment score of 0.79 beat Avalo Therapeutics' score of 0.40 indicating that Ampio Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ampio Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Avalo Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do institutionals & insiders have more ownership in AMPE or AVTX?

3.1% of Ampio Pharmaceuticals shares are owned by institutional investors. Comparatively, 19.3% of Avalo Therapeutics shares are owned by institutional investors. 3.3% of Ampio Pharmaceuticals shares are owned by company insiders. Comparatively, 45.4% of Avalo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Does the MarketBeat Community believe in AMPE or AVTX?

Avalo Therapeutics received 4 more outperform votes than Ampio Pharmaceuticals when rated by MarketBeat users. Likewise, 26.67% of users gave Avalo Therapeutics an outperform vote while only 0.00% of users gave Ampio Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Ampio Pharmaceuticals	Outperform Votes No Votes	Underperform Votes 5 100.00%
Avalo Therapeutics	Outperform Votes 4 26.67%	Underperform Votes 11 73.33%

Which has better valuation & earnings, AMPE or AVTX?

Ampio Pharmaceuticals has higher earnings, but lower revenue than Avalo Therapeutics. Ampio Pharmaceuticals is trading at a lower price-to-earnings ratio than Avalo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ampio Pharmaceuticals	N/A	N/A	-$16.34M	-$20.60	-0.18
Avalo Therapeutics	$18.05M	0.16	-$41.66M	-$2.14	-0.07

Summary

Avalo Therapeutics beats Ampio Pharmaceuticals on 10 of the 14 factors compared between the two stocks.